8-K: Tonix Pharmaceuticals Presents Promising Data on Mpox Vaccine Candidate TNX-801

Tonix Pharmaceuticals presented data at a symposium highlighting the potential of their TNX-801 vaccine, a synthetic horsepox vaccine, for preventing mpox, showing improved tolerability and efficacy in animal models.

Summary

• Tonix Pharmaceuticals presented data on their TNX-801 vaccine candidate for mpox at a symposium.
• TNX-801 is a live-virus vaccine based on synthesized horsepox, designed for percutaneous administration.
• The vaccine has shown single-dose immune protection against monkeypox challenge with better tolerability than 20th-century vaccinia vaccines in animals.
• TNX-801 is structurally closer to 19th-century live-virus vaccinia vaccines, which were believed to provide long-lasting protection.
• The company highlighted that TNX-801 has shown efficacy in protecting animals against lethal challenge with clade I monkeypox.
• New data indicates improved tolerability in immunocompromised animals and no evidence of spreading to blood or tissues, even at high doses.
• Tonix scientists have found that monkeypox clade IIb from a 2022 isolate is 10,000 to 100,000-fold more attenuated than clade IIa isolates from 2003.
• The company believes TNX-801 can be manufactured at scale economically with standard shipping and storing requirements.
• Tonix is also developing TNX-1800, a horsepox-based vaccine for COVID-19, which has been selected by the NIH's Project NextGen for clinical trials.

Sentiment

Score: 8

Explanation: The document presents very positive data on the TNX-801 vaccine candidate, highlighting its potential advantages over existing vaccines. The selection of TNX-1800 for NIH's Project NextGen further boosts the positive sentiment. However, the document also acknowledges the risks associated with drug development, which prevents a perfect score.

Positives

• TNX-801 has shown strong protection against monkeypox in animal models, including against the more lethal clade I strain.
• The vaccine has demonstrated improved tolerability compared to 20th-century vaccinia vaccines, with no significant weight loss or illness in animal studies.
• TNX-801 is designed for single-dose administration, which is more convenient than the two-dose regimens of some other vaccines.
• The vaccine's percutaneous delivery method is an advantage over vaccines requiring sterile injection.
• TNX-801 has shown the potential to block forward transmission of the virus.
• The vaccine is believed to be stable in lyophilized form, eliminating the need for ultra-cold storage.
• The company has a collaboration to develop GMP manufacturing processes for TNX-801 with Bilthoven Biologics.
• TNX-1800, the COVID-19 vaccine candidate, has been selected for clinical trials by the NIH's Project NextGen.

Negatives

• The document notes that the new and more lethal clade I monkeypox has not yet been fully analyzed.
• The company's product candidates are investigational and have not been approved for any indication.
• There are risks related to obtaining FDA clearances or approvals and noncompliance with FDA regulations.
• The company faces risks related to the timing and progress of clinical development of their product candidates.
• The company has a need for additional financing.

Risks

• The company faces risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations.
• There are risks related to the failure to successfully market any of their products.
• The timing and progress of clinical development of their product candidates are uncertain.
• The company has a need for additional financing.
• There are uncertainties of patent protection and litigation.
• The company faces uncertainties of government or third-party payor reimbursement.
• The company has limited research and development efforts and dependence upon third parties.
• The company faces substantial competition.

Future Outlook

The company plans to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for TNX-102 SL for the management of fibromyalgia. They also plan to continue development of TNX-801 and TNX-1800.

Management Comments

• Seth Lederman, M.D., Chief Executive Officer of Tonix, stated, 'We are excited to develop TNX-801 to prevent mpox and control mpox epidemics.'
• Dr. Lederman also said, 'We believe TNX-801 can be manufactured at scale economically with standard shipping and storing requirements.'
• Dr. Lederman noted, 'We recently announced a collaboration to develop GMP manufacturing processes for TNX-801 with Bilthoven Biologics.'

Industry Context

This announcement is significant given the recent mpox outbreaks and the need for more effective and safer vaccines. The development of a single-dose, percutaneously administered vaccine like TNX-801 could be a major advancement in the field. The selection of TNX-1800 for NIH's Project NextGen also highlights the importance of developing new vaccine platforms for emerging infectious diseases.

Comparison to Industry Standards

• The document compares TNX-801 to ACAM2000, a live-virus vaccine from Emergent Technologies, noting that ACAM2000 carries a Black Box warning due to tolerability issues, while TNX-801 has shown improved tolerability in animal models.
• It also compares TNX-801 to Jynneos from Bavarian Nordic, a non-replicating vaccine requiring a two-dose regimen, highlighting that TNX-801 is a single-dose vaccine.
• The document references studies comparing mRNA vaccines to modified vaccinia Ankara (MVA) vaccines, suggesting that TNX-801's activity compares favorably to both.
• The document also references historical data on the effectiveness of horsepox-like vaccines in preventing smallpox, suggesting that TNX-801 may offer similar protection against mpox.

Stakeholder Impact

• Shareholders may benefit from the positive data and potential for future revenue from the vaccine candidates.
• Employees may be impacted by the company's growth and development efforts.
• Customers (healthcare providers and patients) may benefit from the availability of new and improved vaccines.
• Suppliers may benefit from increased demand for materials and services.
• Creditors may be impacted by the company's financial performance and ability to repay debts.

Next Steps

• The company plans to continue the development of TNX-801 and TNX-1800.
• Tonix will submit a New Drug Application (NDA) to the FDA in the second half of 2024 for TNX-102 SL.
• NIH plans to conduct a Phase 1 trial of TNX-1800.

Key Dates

Keywords

Mpox, Vaccine, TNX-801, Horsepox, Vaccinia, Immunology, Infectious Disease, Synthetic Biology, COVID-19, TNX-1800